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Methods: A retrospective analysis of 28 patients of acute heart
failure (all due to different spectrum of acute coronary syndrome)
in whom ivabradine was used was done. All of them had an
ejection fraction of <50%, resting heart rate >70 bpm and SBP> 100
mm Hg without inotropes. The patients were receiving standard
guideline directed therapy including beta blockers wherever
indicated. Ivabradine was started in a dose of 2.5 mg BD and
increased upto 7.5 mg BD in accordance with the patient’s clinical
condition. The patient’s clinical parameters were recorded at the
time of initiation of Ivabradine and 24-hours and 7 days after
initiation of therapy.
Results: A total of 28 patients (mean age 60.3 years, 20 males)
constituted the study group. Baseline mean Heart rate (HR) was 96
(70-128) bpm and systolic Blood pressure (SBP) was 110 mm
Hg(100-134mm Hg). Patients in NYHA II, III and IV numbered 19, 9
and 0 respectively when the therapy with ivabradine was started.
HR decreased by 2.7 ± 0.2 bpm after 24 hours (p¼NS) and 14.3 ± 7.2
bpm at day 7 (p ¼ 0.008). The systolic blood pressure decreased by
2.4mmHg after 24 hours (p¼NS) and 4.1mmHg at day 7 (p¼0.091)
. Patients in NYHA class II and III at 24 hours was 20 and 8
respectively. At 7 days, 8 patients were in NYHA I, 17 in NYHA II
and 3 in NYHA III. No worsening of NYHA class was noted in any
patient at 7 days.
Conclusion: Initiating Ivabradine in patients of acute heart failure
during hospital stay is both safe and effective.
The safety and efficacy of renal denervation
therapy in chronic heart failure patients using a
standard cardiac ablation catheter
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Background: Chronic heart failure is associated with sympathetic
activation characterised by elevated circulating norepinephrine
levels which are linked to cardiovascular morbidity andmortality.
Surgical renal denervation has been shown to improve both renal
and ventricular function, although all these studies have been
conducted on animal models so far. In humans the safety and
efficacy of renal denervation therapy has been studied in treat-
ment of drug resistant hypertension only. Limited data exist
regarding renal denervation therapy in chronic heart failure pa-
tients. All these studies have used specifically desingnedcathers
which are not cost effective especially in developing countries.
Our study is the first randomised study of renal denervation
done in patients of chronic heart failure using standard radio
frequency cardiac ablation cathers.
Aim and objective: To demonstrate the safety and efficacy of renal
denervation therapy in chronic heart failure patients using the
standard cardiac radiofrequency ablation catheter.
Method: Thirty eight patients with chronic heart faiulre with
LVEF< 40 % on optimal heart failure therapy were enrolled and
randomized into two group:
(a) interventional group (n ¼ 18) and; (b) conservative group (n ¼
20). Out of the 18 patients in the interventional arm, 15 underwent
successful bilateral renal denervation. In all these patients stan-
dard radio frequency cardiac ablation cather was used. Patients
were admitted for pre-procedure baseline assessments and in-
patient observation for 2 days following denervation. Follow up
was done at 1st week, one month, three months, six months and
one year.
Results: No significant haemodynamic disturbances were noted
during the acute phase post renal denervation. Over one year of
followup there was a non-significant trend to blood pressure
reduction (Dsystolic 5.2±5.9 mm Hg, p¼0.35; Ddiastolic 1.2± 3
mm Hg, p¼0.70). No hypotensive or syncopal episodes were re-
ported. Renal function remained stable (Dcreatinine 5.7±8.4
mmol/l, p¼0.52 and Durea 1.0±1.0 mmol/l, p¼0.33).
As compared to the conservative group, in the interventional
group there was a significant difference at 12 months of follow
with respect to increase in 6 min walk test(537±103meter to
603±119 vs 499± 98 to 533±99 p 0.001) , increase in LVEF(27.3±11 to
33.1±13 vs 28.1±12 to 30.1± 14 p< 0.001) and reduction in NT -pro
BNP levels(1896 ±79pg/ml to1324±67 pg/ml vs 1903±95 to 1765±89
p<0.001)
Conclusions: This study found no procedural or post procedural
complications following renal denervation in patients with
chronic systolic heart failure at 12 months follow-up. Results
suggested a significant improvement in interventional group as
compared to conservative group in terms of 6 min walk test, LVEF
and NT pro BNP levels.
Hence, to conclude sympathetic renal denervation is not only
safe but also efficient in patients of chronic heart failure and
standard cardiac ablation cathers can be as effective and safe as
specially designed cathers.
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Background: Presence of hsTnT was also a strong independent
predictor of mortality and provided prognostic information in
heart failure patient increamental to that provided by other
powerful predictor of outcome like BNP.
Methods: In this study 100 patient of acute decompensated heart
failure who were admitted in the cardiology indoor of IPGME&R,
SSKM hospital kolkata between February 2012 to September 2013
were enrolled. It is prospective observational study.within 24
hours of admission quantitative serum analysis was done and the
positive were categorized as troponin T positive(>50ng/l) or
troponin T negative(>50ng/l).
Results: The study shows significant number of patients(n¼66)
were positive for hsTnT. Systolic blood pressure is reduced sig-
nificantly(p<0.001) on follow up study in hsTnT positive patients.
FBS(>126mg/dl) is significantly increased on admission in hsTnT
positive patients(131.4+42.9) in compared to hsTnT negative
patients.(mean+SD¼98+33.2) (p¼0.049). LVID(d) is singificantly
increased at admission, discharge and follow up study. The
reduction of EF(%) is statistically significant(p¼0.03CI¼0.75 to 0.94
and odd ratio 0.84) in the three months follow up study. Duration
of stay in hospital is more in hsTnT positive patients than
troponin negative patients as detailed in descriptive study above.
The value become statistically significant in our study(p¼0.001).
Conclusion: The patients with troponin T positivity show higher
mortality (both in hospital and outside) and recurrent hospitali-
zation in comparison with troponin T negative patients. Duration
of stay in hospital is higher for hsTnT positive patients when
compared with troponin negative patients. NYHA class and
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ejection fraction changed in a negative direction in patients of
ADHF who are troponin positive.
Though from the present study, we got some positive directions
in making prognostic correlation of ADHF patients with troponin
positivity, further large prospective randomized trials are neces-
sary before coming to definite conclusion in making recommen-
dation for doing quantitative troponin T in all patients of acute
decompensated heart failure for prognosis and guiding therapy.
Post renal transplantation e Effect on ventricular
dysfunction and pulmonary hypertension
Gandhamdara Kiran Kumar
Narayana Medical College and Hospital, Nellore, India
Background: Heart disease is a frequent complication of chronic
kidney disease and the major cause of death in patients on renal
replacement therapy. The purpose of this study was to evaluate
the impact of successful renal transplantation on systolic and
diastolicventricular dysfunction and pulmonary arterial hyper-
tension in patients with chronic kidney disease (CKD).
Methods: The study included 35 patients >18 years of age with
CKD who had successful kidney transplantations. Ventricular
function and pulmonary arterial pressure were evaluated by
echocardiography before and 1 year after transplant.
Results: The mean age of subjects was 40 _+ 14 years, and 63%
were men. Mean left ventricular ejection fraction (LVEF) was 52 +_
16%. Before transplant, 28 (80%) of the patients had ventricular
dysfunction (34.3% diastolic and 45.7% systolic). Pulmonary arte-
rial hypertension was found in 48.6%. Ventricular dysfunction
was associated with dialysis of >2 years duration before trans-
plant. The LVEF of the entire group increased from 52% to 64% (P <
.001) by 12 months after kidney transplant. Left ventricular di-
ameters, wall thickness, and pulmonary arterial systolic pressure
decreased significantly after transplantation Echocardiograms
became normal 1 year after transplant in 8 (66.7%) of the patients
with diastolic dysfunction and 9 (56.2%) with systolic dysfunction,
and diastolic dysfunction persisted in 5 (31.2%).
Conclusions: Renal transplantation has led to considerable
improvement in left ventricular systolic and diastolic function as
well as pulmonary arterial pressure of patients with CKD, optimal
treatment for dysfunction and transplant as soon as possible is
recommended.
Echocardiographic parameters and cardiac failure
in end-stage renal disease on vigorous
hemodialysis
Gandhamdara Kiran Kumar, Ashutosh Kumar
Narayana Medical College and Hospital, Nellore, India
Background: Abnormal Echocardiographic parameters are seen in
all patients starting dialysis therapy and are associated with the
development of cardiac failure and death.
Objective: to know whether regression of cardiac abnormalities is
associated with an improvement in prognosis with vigorous renal
dialysis.
Methods: As part of a prospective cohort study with mean follow-
up of 6 mo, 57 patients had echocardiography at inception and
after 1 week of vigorous renal dialysis therapy.
Results: Improvements in left ventricular (LV)mass index, volume
index, and fractional shortening were seen in 48, 48, and 46%,
respectively. Twenty-four patients had developed cardiac failure
by 6 months of dialysis therapy. Twenty-six percent of the
remaining 27 patients subsequently developed new-onset cardiac
failure. The mean changes in LV mass index were 17 g/m(2) in
those who subsequently developed cardiac failure compared with
0 g/m(2) among those who did not (P ¼ 0.05). The corresponding
values were -8 versus 0% for fractional shortening (P < 0.0001).
Conclusion: Regression of LV abnormalities is associated with an
improved cardiac outcome in endstage renal disease patients on
vigorous dialysis.
Heart failure etiologies, management and
outcomes in hospitalized and clinic-based
patients
Rajeev Gupta, Sanjeeb Roy, Vaibhav Grover, Raghav Chaudhary,
K.K. Sharma, Sharad Chaturvedi, Bhawani Mishra
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Background: There are no contemporary data on etiologies,
management and outcomes of heart failure in India. To determine
etiologies andmanagement of heart failure in hospital- and clinic-
based patients in India we performed a study.
Methods: Successive patients presenting to a tertiary care non-
government hospital with acute decompensated heart failure
(ADHF, n¼102) and stable heart failure (SHF, n¼179) were enrolled.
Both the groups were followed for 90 days. Etiology of heart failure
was diagnosed using clinical examination and echocardiography.
Details of in-hospital, discharge and 90-day medications were
obtained in both groups. Outcomes (mortality) data were recor-
ded. Descriptive statistics are reported.
Results: Prevalence of various cardiovascular diseases in ADHF vs
SHF patients, respectively, was coronary heart disease 50.0 vs
53.6%, hypertension 60.8 vs 44.7%, cardiomyopathy 16.7vs 7.3%,
rheumatic heart disease 4.9 vs 14.0%, and hypertrophic cardio-
myopathy 1.0 vs 7.3%. Heart failure with normal ejection fraction
was in 23 ADHF and 2 SHF patients. In-hospital treatments
included diuretics, nitrates, angiotensin converting enzyme (ACE)
inhibitors, digoxin, anticoagulants and vasopressors. At discharge
significantly greater number of patients with ADHF vs SHF were
on loop-diuretics (95.5 vs 78.2%), anti-platelets (74.4 vs 64.2%) and
anti-arrhythmics (23.3 vs 6.1%) while lesser were on thiazides (1.5
vs 9.5%), anti-aldosterone (33.4 vs 43.0%), ACE inhibitors (30.0 vs
35.2%), angiotensin receptor blockers (ARBs, 4.5 vs 40.8%) and
beta-blockers (33.4 vs 45.8%) (p<0.05). Use of digoxin {28.9 vs
31.8%), nitrates (32.2 vs 30.7%) and anticoagulants (11.1 vs 8.9%)
was similar. At 90 days, in ADHF vs SHF patients lower use of ACE
inhibitors (42.4 vs00.0%) and ARBs (4.5 vs. 0.0%) and similar use of
beta-blockers (48.5 vs00.0%) was observed. In ADHF patients, in-
hospital mortality was 10.3% (n¼11). Cumulative 90-day mortality
in ADHF was 45.0% (n¼46) while in SHF patients was 1.1% (n¼7)
(p<0.05).
Conclusions: This study shows that coronary and hypertensive
heart diseases are important causes of heart failure at a tertiary-
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